Routes of
administration Oral CAS Number 443144-26-1 UNII UL09X1D9EM Pubchem 6433122 ChemSpider ID 4938310 | ATC code none PubChem CID 6433122 Molar mass 376.43 g/mol ChEMBL ID 1215661 | |
 | ||
Legal status In general: uncontrolled | ||
How to pronounce pruvanserin
Pruvanserin (EMD-281,014, LY-2,422,347) is a selective 5-HT2A receptor antagonist which was under development by Eli Lilly and Company for the treatment of insomnia. It was in phase II clinical trials in 2008 but appears to have been discontinued as it is no longer in the company's development pipeline. In addition to its sleep-improving properties, pruvanserin has also been shown to have antidepressant, anxiolytic, and working memory-enhancing effects in animal studies.
References
Pruvanserin Wikipedia(Text) CC BY-SA